Skip to main content

Table 1 Patient demographics and tumor characteristics

From: Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients

Patient Age (years) Treatment regimes ER PR HER2
neu
Diameter (mm)a TNM stage
1 61 4×AC–12×paclitaxel + + 24 T2N1M0
2 50 3×FEC–3×docetaxel + + 30 T4N1M0
3R 57 3×FEC–3×docetaxel + + 35 T2N0M0
3L 57 3×FEC–3×docetaxel + + 15 T1N0M0
4 43 3×FEC–3×docetaxel + 24 T2N0M0
5 59 3×FEC–3×docetaxel + + 32 T2N1M0
6 39 3×FEC–3×docetaxel + 110 T3N2M0
7 55 6×Taxotere–AC 32 T2N0Mx
8 63 6×Taxotere–AC + + 15 T2N1Mx
9 35 6×Taxotere–AC 30 T2N0M0
  1. AC adriamycin and cyclophosphamide, ER estrogen receptor, FEC 5-fluorouracil, epirubicin, and cyclophosphamide, HER2 human epidermal growth factor receptor 2, L left, PR progesterone receptor, R right, TNM tumor, nodes, metastasis (classification of malignant tumors)
  2. a Measurement performed on 3 T magnetic resonance imaging acquired for standard clinical practice